Senologie - Zeitschrift für Mammadiagnostik und -therapie, Table of Contents Senologie - Zeitschrift für Mammadiagnostik und -therapie 2009; 6(4): 231-236DOI: 10.1055/s-0030-1247188 Review© Georg Thieme Verlag KG Stuttgart ˙ New YorkOnkologie - Chemotherapie des metastasierten MammakarzinomsR. BartschG.G. StegerRecommend Article Abstract Full Text References Literatur 01 Beslija S , Bonneterre J , Burstein H , et al . Second consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2007; 18 215-225 02 Miles D , Minckwitz G von , Seidman A D. Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist. 2007; 7 (Suppl 6) 13S-19S 03 Fossati R , Confalonieri C , Torri V , et al . Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trias involving 31,510 women. J Clin Oncol. 1998; 16 3439-3460 04 O'Shaughnessy J , Miles D , Vukelja S , et al . Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002; 20 2812-2823 05 Sledge G W, Neuberg D , Bernardo P , et al . Phase III trial of doxorubicin, paclitaxel and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193). J Clin Oncol. 2003; 21 588-592 06 Koroleva I , Wojtukiewicz M , Zaluski J , et al . Preliminary results of a phase II randomized trial of taxotere (T) and doxorubicin (A) give in combination or sequentially as first line chemotherapy (CT) for metastatic breast cancer (MBC). Proc Am Soc Clin Oncol. 2001; 20 abstract 117 07 Tomova A , Brodowicz T , Tzekova V , et al . Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine. J Clin Oncol. 2008; 26 (Suppl. 15) 11065 08 Muss H B, Case L D, Richards 2nd F, et al . Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med. 1991; 325 1370-1371 09 Falkson G , Gelman R S, Pandya K J, et al . Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol. 1998; 16 1669-1676 10 Gennari A , Amadori D , de Lena M , et al . Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol. 2006; 24 3912-3918 11 Alba E , Ruiz-Borrego M , Martin M , et al . Prolongation of TTP by maintenace therapy with PLD in amulticenter phase III randomized trial following standard chemotherapy for MBC: GEICAM 2001-01 study. J Clin Oncol. 2007; 25 (Suppl. 18) 1007S 12 Gennari A , Sormani M , Bruzzi P , et al . A meta-analysis of chemotherapy duration in metastatic breast cancer (MBC). J Clin Oncol. 2008; 26 (Suppl. 15) 1067 13 Hortobbagyi G N. Treatment of breast cancer. N Engl J Med. 1998; 339 974-984 14 Pronzato P , Rondini M . First line chemotherapy of metastatic breast cancer. Ann Oncol. 2006; 17 (Suppl. 5) 165S-168S 15 A'Hern R P, Smith I E, Ebbs S R. Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Br J Cancer. 1993; 67 801-805 16 Gralow J R. Optimizing the treatment of metastatic breast cancer. Breast Cancer Res Treat. 2005; 89 (Suppl. 1) 9S-15S 17 Michelotti A , Venturini M , Tibaldi C , et al . Single agent epirubicin as first line chemotherapy for metastatic breast cancer. Breast Cancer Res Treat. 2000; 59 133-139 18 Batist G , Ramakrishnan G , Rao C S, et al . Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol. 2001; 19 1444-1454 19 Harris L , Batist G , Belt R , et al . Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002; 94 25-36 20 Biganzoli L , Coleman R , Minisini A , et al . A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer. Crit Rev Oncol Hematol. 2007; 61 84-89 21 Ghersi D , Wilcken N , Simes R J. A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer. 2005; 93 293-301 22 Piccart-Gebhart M J, Burzykowski T , Buyse M , et al . Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol. 2008; 26 1980-1986 23 Paridaens R , Biganzoli L , Bruning P , et al . Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer randomized study with cross-over. J Clin Oncol. 2000; 18 724-733 24 Seidman A D, Berry D , Cirrincione C , et al . Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008; 26 1642-1649 25 Chan S , Friedrich K , Noel D , et al . Prospective randomised trial of Docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1999; 12 2341-2354 26 Langley R E, Carmichael J , Jones A L, et al . Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. J Clin Oncol. 2005; 23 8322-8330 27 Lück H J, Thomssen C , Untch M , et al . Multicentric phase III study in first line treatment of advanced breast cancer (ABC): Epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC) - A study of the AGO Breast Cancer Group. Proc Am Soc Clin Oncol. 2000; 19 abstract 280 28 Biganzoli L , Cufer T , Bruning P , et al . Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial. J Clin Oncol. 2002; 20 3114-3121 29 Jassem J , Pienkowski T , Pluzanska A , et al . Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: Final results of a randomized phase III multicenter trial. J Clin Oncol. 2001; 19 1707-1715 30 Mackey J R, Paterson A , Dirix L , et al . Final results of the phase III randomised trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol. 2002; 21 abstract 137 31 Nabholtz J M, Falkson G , Campos D , et al . Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial. J Clin Oncol. 2003; 21 968-975 32 Bontenbal M , Creemers G J, Braun H J, et al . Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: Results of a Dutch community setting trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol. 2005; 23 7081-7088 33 Bonneterre J , Dieras V , Tubiana-Hulin M , et al . (2004) Phase II multicentre randomised study of deocetaxel plus epirubicinversus 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br J Cancer. 2004; 91 1466-1471 34 Zielinski C , Beslija S , Mrsic-Krmpotic Z , et al . Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial. J Clin Oncol. 2005; 23 1401-1408 35 Stockler M , Sourjina T , Grimson P , et al . A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC). J Clin Oncol. 2007; 25 (Suppl. 18) 1031S-1013S 36 Marty M , Fumoleau P , Adenis A , et al . Oral vinorelbine pharmacokinetics and absolute bioavailability in patients with solid tumours. Ann Oncol. 2001; 12 1643-1649 37 Bartsch R , Wenzel C , Pluschnig U , et al . Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: results from a pilot trial. Cancer Chemother Pharmacol. 2006; 57 554-558 38 Fumoleau P , Delgado F M, Delozier T , et al . Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol. 1993; 11 1245-1252 39 Garcia-Conde J , Lluch A , Martin M , et al . Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol. 1994; 5 854-857 40 Romero A , Rabinovich M G, Vallejo C T, et al . Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol. 1994; 12 336-341 41 Weber B L, Vogel C , Jones S , et al . Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol. 1995; 13 2722-2730 42 Bruno S , Puerto V L, Mickiewicz E , et al . Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience. Am J Clin Oncol. 1995; 18 392-396 43 Joensuu H , Kellokumpu-Lehtinen P L, Bono P , et al . Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006; 354 809-820 44 Pajk B , Cufer T , Canney P , et al . Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from EORTC 10001 randomized phase II trial. Breast. 2008; 17 180-185 45 Hess D , Koberle D , Thurlimann B , et al . Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99). Oncology. 2007; 73 228-237 46 Ejlertsen B , Mouridsen H T, Langkjer S T, et al . Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403). J Clin Oncol. 2004; 22 2313-2320 47 Moorsel CJA Van , Peters G J, Pinedo H M. Gemcitabine: future prospects of single-agent and combination studies. Oncologist. 1997; 2 127-134 48 Feher O , Vodvarka P , Jassem J , et al . First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. Ann Oncol. 2005; 16 899-908 49 Jones S E, Erban J , Overmoyer B , et al . Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 2005; 23 5542-5551 50 Gradisher W J, Tjulandin S , Davidson N , et al . Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor-oil based paclitaxel in women with breast cancer. J Clin Oncol. 2005; 23 7794-7783 51 Gradisher W , Krasnojon D , Cheporov S , et al . Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC). J Clin Oncol. 2007; 25 (Suppl. 18) 1032S 52 Harvey V , Mouridsen , Semiglazov V , et al . Phase III trial comparing three doses of deocetxael for second-line treatment of advanced breast cancer. J Clin Oncol. 2006; 18 1212-1219 53 Burstein H J, Manola J , Younger J , et al . Docetaxel administered on a weekly basis for metastatic breast cacner. J Clin Oncol. 2000; 18 1212-1219 54 Albain K S, Nag S M, Calderillo-Ruiz G , et al . Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008; 26 3950-3957 55 Chan S , Romieu G , Huober J , et al . Phase III Study of Gemcitabine Plus Docetaxel Compared With Capecitabine Plus Docetaxel for Anthracycline-Pretreated Patients With Metastatic Breast Cancer. J Clin Oncol. 2009; 27 1753-1760 56 Overmoyer B . Options for the treatment of patients with taxane-refractory metastatic breast cancer. Clin Breast Cancer. 2008; 8 (Suppl. 2) 615-705 57 Thomas E S, Gomez H L, Li R K, et al . Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007; 25 5210-5217 58 Martin M , Ruiz A , Munoz M , et al . Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol. 2007; 8 219-225 59 Ershler W B. Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer. Oncologist. 2006; 11 325-335 60 Low J A, Wedam S B, Lee J J, et al . Phase II clinical trial of Ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol. 2005; 32 2726-2734 61 Weber B L, Vogel C , Jones S , et al . Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol. 1995; 13 2722-2730 62 Gasparini G , Caffo O , Barni S , et al . Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase study. J Clin Oncol. 1994; 21 2094-2101 63 Zelek L , Barthier S , Riofrio M , et al . Weekly vinorelbine is an effective palliative regimen after failure with anthracycline and taxanes in metastatic breast carcinoma. Cancer. 2001; 92 2267-2272 64 Jones S , Winer E , Vogel C , et al . Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol. 1995; 13 2567-2574 65 Verma S , Wong N S, Trudeau M , et al . Survival differences observed in metastatic breast cancer patients treated with capecitabine when compared with vinorelbine after pretreatment with anthracycline and taxane. Am J Clin Oncol. 2007; 30 297-302 66 Finek J , Holuber Jr L, Svoboda T , et al . A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer. Anticancer Res. 2009; 29 667-670 67 Nole F , Crivellari D , Mattioli R , et al . Phase II study of an all-oral vinorelbine with capecitabine in patients with metastatic breast cancer. Cancer Chemother Pharmacol 2009 [Epub ahead of print]. 68 Gampenrieder S P, Bartsch R , Pluschnig U , et al . An all-oral chemotherapy in locally advanced and metastatic breast cancer. Onkologie. 2008; 31 (Suppl. 4) 165S-166S 69 Estevez L G, Batista N , Sanchez-Rovira P , et al . A phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Clin Breast Cancer. 2008; 8 194-154 70 Carmichael J , Possinger K , Phillip P , et al . Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol. 1995; 13 2731-2736 71 Blackstein M , Vogel C L, Ambinder R , et al . Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology. 2002; 62 2-8 72 Brodowicz T , Kostler W J, Moslinger R , et al . Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer. Breast. 2000; 9 228-342
